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ABSTRACT
Rapid, accurate and inexpensive diagnosis of bacterial meningitis is critical for patient management.
This study describes the development and evaluation of a multiplex PCR assay for the detection of
Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus inﬂuenzae type b, which globally account
for 90% of cases of bacterial meningitis. The single-tube assay, based on the ctrA, ply and bex targets,
respectively, enabled detection of 5–10 pg DNA. When the assay was tested with clinical samples
(n = 425), its sensitivity for the three targets was 93.9%, 92.3% and 88%, respectively, while the overall
speciﬁcity and positive predictive value of the assay was 100%. The negative predictive value was 99.1–
99.5%. The methodology permits rapid and accurate detection of the three main pathogens that cause
bacterial meningitis.
Keywords Diagnosis, Haemophilus inﬂuenzae, meningitis, Neisseria meningitidis, PCR, Streptococcus pneumoniae
Original Submission: 6 October 2004; Revised Submission: 9 December 2004; Accepted: 23 December 2004
Clin Microbiol Infect 2005; 11: 386–390
INTRODUCTION
Meningitis receives a high level of medical, public
and media attention because of its rapid onset and
high level of morbidity and mortality [1]. The
rapid progression of symptoms and potentially
devastating effects of this disease necessitate early
recognition and immediate treatment [2]. Neisseria
meningitidis, Streptococcus pneumoniae and Haemo-
philus inﬂuenzae type b are the main causes of
bacterial meningitis [3–5], globally accounting for
90% of reported cases of acute bacterial menin-
gitis in infants and children aged > 60 days [6].
Bacterial pathogens with increased virulence
and transmissibility have highlighted the import-
ance of effective methods for rapid identiﬁcation
and epidemiological surveillance. Rapid identiﬁ-
cation has important public health implications,
particularly with regard to case contact manage-
ment, detecting and evaluating clusters of cases,
and intervening in outbreaks. Developments in
meningococcal and pneumonococcal polysaccha-
ride–protein conjugate vaccines have increased the
need for accurate laboratory conﬁrmation of these
infections in order to monitor the effects of vaccine
implementation and their continuing efﬁcacy [7].
Until the introduction of the meningococcal sero-
group C vaccine, the incidence of conﬁrmed cases
of meningococcal disease continued to increase
during a time of raised public and medical aware-
ness and improved laboratory techniques [8,9]. For
many years, epidemiological investigations of out-
breaks of meningococcal disease have relied on the
serological characterisation of isolates. This cul-
minated in the development of a characterisation
scheme that included the capsular polysaccharide
(serogroup) and two of the major outer-membrane
protein antigens, PorA and PorB [10].
More recently, PCR-based identiﬁcation meth-
ods have been used by the National Meningo-
coccal Reference Laboratory in Greece to conﬁrm
cases of N. meningitidis, especially those in which
early antibiotic treatment prevents detection by
culture [11]. Target genes investigated for iden-
tiﬁcation of N. meningitidis in cultured micro-
organisms or clinical specimens from infected
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patients include IS1106 [12], porA [13] and 16S
rRNA [14]. PCR assays have also been developed
for the conserved regulatory gene, crgA [15], and
the ctrA gene [16], which is involved in transport
of capsular polysaccharide [17]. Advances in real-
time ampliﬁcation technology have enabled
selective ampliﬁcation of multiple genes in one
reaction by utilising spectrally distinct phospho-
ramidite dye-labelled probes [18]. Despite its
high efﬁciency, this method is expensive and
technically challenging; thus its routine use is
restricted.
The present study describes the development
and evaluation of a single-tube multiplex PCR for
the simultaneous detection of N. meningitidis,
S. pneumoniae and H. inﬂuenzae type b in clinical
samples as a tool for improved non-culture
diagnosis of the three major causes of bacterial
meningitis.
MATERIALS AND METHODS
Patient specimens
During a 2-year period (2002–2003), 425 samples from 336
patients were sent to the National Meningococcal Reference
Laboratory, Athens, from different hospitals throughout
Greece. These consisted of 227 blood samples, 194 cerebrospi-
nal ﬂuid (CSF) samples, three pleural samples and one
bronchial sample. Details of the collection of clinical data
and samples have been published previously [11].
Patient samples were classiﬁed as follows: (1) culture-
conﬁrmed cases with one of the three bacterial targets isolated
from either blood and ⁄ or CSF (53 patients; 36 blood samples,
32 CSF samples, three pleural ﬂuid samples and one bronchial
ﬂuid sample); (2) culture-negative cases, but with Gram-
negative or -positive cocci visualised in a direct smear, or
antigen detected in CSF (14 patients; nine blood samples, 12
CSF samples); (3) clinically suspected cases of bacterial
meningitis, but with culture and other tests yielding negative
results (54 patients; 41 blood samples, 33 CSF samples); (4)
cases with clinically diagnosed bacterial meningitis caused
by other bacteria (65 patients; 33 blood samples, 41 CSF
samples), identiﬁed as Brucella (n = 1), Listeria monocytogenes
(n = 4), Staphylococcus aureus (n = 7), Staphylococcus epidermidis
(n = 5), group A streptococci (n = 7), group B streptococci
(n = 6), Cryptococcus (n = 2), amoebae (n = 1), Escherichia coli
(n = 10), Klebsiella pneumoniae (n = 12), Enterococcus faecalis
(n = 6), Citrobacter koseri (n = 3), Salmonella Typhimurium
(n = 4), Acinetobacter baumannii (n = 2) and Enterobacter cloacae
(n = 4); and (5) cases with clinically diagnosed viral meningitis
(150 patients; 108 blood samples, 76 CSF samples).
Bacteria
All bacterial isolates from patient samples were sent to the
National Meningococcal Reference Laboratory by each refer-
ring hospital for further identiﬁcation. Bacterial isolates from
blood or CSF samples were cultured on chocolate and ⁄ or
blood agar and grown at 37C in CO2 5% v ⁄v. Latex
agglutination kits (Pastorex; Sanoﬁ Diagnostics, Marnes-
la-Coquette, France; or Wellcogen Bacterial Antigen Kit;
Abbott Murex, Dartford, UK) were used for detection of
antigens in CSF.
DNA isolation
Bacterial colonies were suspended in 500 lL of sterile double-
distilled H2O, vortexed, boiled for 15 min, and centrifuged at
20 000 g for 12 min. The supernatant was retained and the
DNA concentration was estimated spectrophotometrically.
DNA was extracted from whole blood samples with
Nucleospin kits (Macherey-Nagel, Du¨ren, Germany) according
to the manufacturer’s instructions.
CSF, pleural or bronchial ﬂuid samples were processed as
described by Zambarti et al. [19]. In brief, 500 lL of sample
was centrifuged at 1700 g for 10 min. The supernatant was
discarded to leave 150 lL, which was added to a mixture of
650 lL of sterile double-distilled H2O and 150 lL of Che-
lex ⁄Tween-80 buffer. The samples were then heated at 100C
for 30 min, and centrifuged at 10 000 g for 8 min.
PCR ampliﬁcation
Ampliﬁcation reactions (50 lL) contained 0.6 lM each oligo-
nucleotide primer (Sigma-Aldrich, Seezle, Germany), 3 mM
MgCl2, 200 lM dNTPs, 1· PCR buffer, 1 U of Taq DNA
polymerase (Abgene, Epsom, UK) and 20 lL of DNA sample.
PCR conditions were 95C for 5 min, followed by 35 cycles of
95C for 25 s, 57C for 40 s and 72C for 1 min in a Robocycler
Gradient 96 Cycler (Stratagene, La Jolla, CA, USA). Amplicons
were visualised under UV ﬂuorescence following electropho-
resis in agarose 3.5% w ⁄v gels and staining with ethidium
bromide. Positive controls of DNA from standard strains of
N. meningitidis, S. pneumoniae and H. inﬂuenzae, as well as
negative controls, were included in each assay.
Speciﬁc primers for the N. meningitidis ctrA gene, the
H. inﬂuenzae bex gene and the S. pneumoniae ply gene were
based on those described previously [18], which gave ampl-
icons of 110, 99 and 80 bp, respectively. However, in order to
distinguish more readily between the amplicon sizes by
electrophoresis, a new forward bex primer was designed using
the Primer3 software (http://frodo.wi.mit.edu/cgi-bin/pri-
mer3/primer3_http://www.cgi) [20] to give amplicon sizes
of 181, 110 and 80 bp, respectively (Table 1).
Serial dilutions of spectrophotometrically quantiﬁed DNA
(500–1 pg ⁄ 50-lL reaction) from each organism were ampliﬁed
with the individual and multiplex assays to determine the
sensitivities of the assays. Speciﬁcities were tested with DNA
extracted from Pseudomonas aeruginosa, b-haemolytic strepto-
cocci (groups A and B), L. monocytogenes, E. cloacae, Staph. epider-
midis,A. baumannii, Staph. aureus andNeisseria lactamica (n = 10).
RESULTS
PCR ampliﬁcation
Ampliﬁcation of each target was unaffected by
the presence of DNA (500–1 pg) from the other
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two organisms. In multiplex reactions, the detec-
tion limits for H. inﬂuenzae, N. meningitidis and
S. pneumoniae, as determined in repeated experi-
ments, were 5 pg, 5 pg and 10 pg, respectively.
The speciﬁcity of the assay was tested with
DNA extracts from N. lactamica and eight organ-
isms likely to be present in CSF and blood
samples. Products of 310 bp were ampliﬁed
from two isolates of N. lactamica, but these
could be distinguished easily from the 110-bp
N. meningitidis product.
Fig. 1 shows examples of the results obtained
when the multiplex PCR was applied to clinical
samples. In total, 425 samples from 336 patients
were tested. Table 2 summarises the results
obtained, grouped according to the organism
involved and the patient category.
Sensitivity and speciﬁcity
The sensitivity of the multiplex PCR assay was
evaluated with data from culture-conﬁrmed and
probable cases (categories 1 and 2, respectively)
for each organism individually (Table 3). Sensi-
tivity ranged from 88% to 93.9%, with positive
predictive values and negative predictive values
of 100% and > 99%, respectively.
The speciﬁcity of the assay was evaluated in
relation to data from 215 patients classiﬁed as
suffering from meningitis caused by viruses
(n = 150) or other bacteria (n = 65). No amplicons
were obtained with any of the samples from these
patients, suggesting that the speciﬁcity of the
assay was 100%.
DISCUSSION
The present study combined primers for the
detection of the ctrA gene of N. meningitidis, the
ply gene of S. pneumoniae and the bexA gene of
H. inﬂuenzae in a multiplex PCR assay. These
genes have been used previously for the clinical
diagnosis of meningitis caused by these three
bacteria [16,21,22], but the present study demon-
strated that these three organisms could be
detected simultaneously in a single tube assay.
After optimisation and evaluation with DNA
extracts from puriﬁed cultures, the multiplex
assay was applied to clinical samples known to
contain small amounts of bacterial DNA in the
presence of large amounts of human genomic
DNA, as well as inhibitors (e.g., haem in blood)
[23,24]. N. meningitidis and H. inﬂuenzae type b
DNA was ampliﬁed efﬁciently when present
at 5 pg ⁄ reaction, while the detection limit for
S. pneumoniae DNA was 10 pg ⁄ reaction; however
this did not appear to affect the detection of
S. pneumoniae in clinical samples.
The sensitivity of the N. meningitidis reaction
was 93.9%, compared to ﬁgures of 88.4–91%
reported previously [18,25]. This sensitivity was
calculated from the results for clinical samples in
categories (1) and (2). In category (1), the PCR-
negative samples were collected 48 h following
antibiotic treatment. In category (2), all the sam-
ples were PCR-positive.
The sensitivity of the S. pneumoniae reaction
was 92.3%, compared to 91.8% in a previous
Fig. 1. Examples of the results obtained when the multi-
plex PCR assay was applied to clinical samples, showing
detection of Haemophilus inﬂuenzae type b (181 bp), Neisse-
ria meningitidis (110 bp) and Streptococcus pneumoniae
(80 bp). Lanes: 1, uX174 HaeIII digest; 2, positive control
for all three targets; 3–13, clinical samples from blood
(lanes 3, 6, 10, 11) or CSF (lanes 4, 5, 7, 8, 9, 12 and 13); 14,
negative control.
Table 1. Oligonucleotides used in
multiplex PCRs to identify the three
main microorganisms that cause
bacterial meningitis
Microorganism
Gene
ampliﬁed Sequence (5¢ ﬁ 3¢) Amplicon size
Haemophilus inﬂuenzae
type b
bex Forward: TATCACACAAATAGCGGTTGG 181 bp
Reverse: GGCCAAGAGATACTCATAGAACGTT
Neisseria meningitidis ctrA Forward: GCTGCGGTAGGTGGTTCAA 110 bp
Reverse: TTGTCGCGGATTTGCAACTA
Streptococcus pneumoniae ply Forward: TGCAGAGCGTCCTTTGGTCTAT 80 bp
Reverse: CTCTTACTCGTGGTTTCCAACTTGA
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study [18]. The sensitivity of the reaction did not
depend on the specimen type, whereas the sen-
sitivities were 100% and 69% for CSF and blood
samples, respectively, in a previous study [26].
However, this gene target has been reported to be
less speciﬁc than some commercially available
kits [27] and may lead to overestimation of the
number of positive samples.
The lowest sensitivity of the three reactions was
recorded for the H. inﬂuenzae type b bex gene.
Seven (87.5%) of eight culture-conﬁrmed cases
were PCR-positive, in contrast to a previous
study, in which the sensitivity was 100% [18].
The clinical sample that was PCR-negative was
collected 3 days after antibiotic treatment.
There was a low number of H. inﬂuenzae type b
cases because of use of the Hib vaccine in Greece
since 1992. The overall speciﬁcity of the assay was
calculated to be 100%. Since cross-reactions
between N. meningitidis and several other species
have been reported in antigen detection assays
[28], and with N. lactamica isolates in molecular
assays [16], the present study included ten
N. lactamica isolates from carriers in the tests for
speciﬁcity. Ampliﬁcation products of 310 bp were
ampliﬁed from two N. lactamica isolates, but these
could be distinguished easily from the 110-bp
N. meningitidis amplicon. The positive predictive
value of the assay for all three targets was
100%, and the negative predictive value was
99.1–99.5%.
Overall, this single-tube PCR assay is a
simple, reliable and easily implemented method
for the conﬁrmation of bacterial meningitis, and
is a rapid and cost-effective way of analysing
large numbers of samples. The development of
the multiplex PCR assay for non-culture detection
of meningococcal DNA will enable conﬁrmation
of cases, particularly when early treatment with
antibiotics impairs detection by culture. This is an
important step towards more accurate recognition
and surveillance of bacterial meningitis infections.
Table 3. Sensitivity of the multiplex PCR assay for detection of the three individual targets
Organism
PCR-positive patients (samples)
Sensitivity PPV NPV
Culture
conﬁrmed Probable
Neisseria meningitidis 25 ⁄ 27 (36 ⁄ 40)
92.6% (90%)
6 ⁄ 6 (9 ⁄ 9)
100% (100%)
93.9%
(95% CI 86.8–93.9)
100%
(95% CI 92.4–100)
99.1%
(95% CI 98–99.1)
Streptococcus pneumoniae 17 ⁄ 18 (22 ⁄ 24)
94.4% (91.7%)
7 ⁄ 8 (7 ⁄ 12)
87.5% (58.3%)
92.3%
(95% CI 83.4–92.3)
100%
(95% CI 90.3–100%)
99.1%
(95% CI 98–99.1%)
Haemophilus inﬂuenzae type b 7 ⁄ 8 (7 ⁄ 8)
87.5% (87.5%)
0 (0) 88%
(95% CI 63.9–88)
100%
(95% CI 73–100)
99.5%
(95% CI 98.7–99.5)
PPV, positive predictive value; NPV, negative predictive value.
Table 2. Detection of bacterial DNA in clinical samples, grouped according to the organism involved and the patient
category
Organism
Culture-conﬁrmed Probable Suspected
Positive PCR Negative PCR Positive PCR Negative PCR Positive PCR Negative PCR
Neisseria meningitidis
Patients (n = 60) 25 ⁄ 27 2 ⁄ 27 6 ⁄ 6 0 18 ⁄ 27 9 ⁄ 27
Samples (n = 85) (blood = 21; CSF = 15) (blood = 2; CSF = 2) (blood = 4; CSF = 5) (blood = 13; CSF = 6) (blood = 9; CSF = 8)
Streptococcus pneumoniae
Patients (n = 48) 17 ⁄ 18 1 ⁄ 18 7 ⁄ 8 1 ⁄ 8 17 ⁄ 22 5 ⁄ 22
Samples (n = 66) (blood = 11; CSF = 7;)
pleural = 3;
bronchial = 1)
(blood = 1; CSF = 1) (blood = 1; CSF = 6) (blood = 4; CSF = 1) (blood = 9; CSF = 11) (blood = 5;
CSF = 5)
Haemophilus inﬂuenzae
type b
Patients (n = 13) 7 ⁄ 8 1 ⁄ 8 0 0 5 ⁄ 5 0
Samples (n = 16) (blood = 1; CSF = 6) (blood = 0; CSF = 1) (blood = 5; CSF = 3)
Other bacteria
Patients (n = 65) 0 20 ⁄ 20 0 0 0 45 ⁄ 45
Samples (n = 74) (blood = 9; CSF = 11) (blood = 24;
CSF = 30)
Virus
Patients (n = 150) 0 2 ⁄ 2 0 148 ⁄ 148 0 0
Samples (n = 184) (blood = 1; CSF = 2) (blood = 107; CSF = 74)
CSF, cerebrospinal ﬂuid.
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